Novo Nordisk is shipping more introductory doses of its blockbuster weight-loss drug Wegovy in the US as it grapples with supply constraints and competition from Eli Lilly & Co. CEO Lars Fruergaard Jorgensen says the company will continue to ramp up supply of its popular weight-loss drug "gradually." He spoke with Bloomberg's Katie Greifeld and Romaine Bostick.

Nobel Laureate in Economics and Professor of Economics Paul Krugman Talks SCOTUS
07:09

California Attorney General Rob Bonta Talks Tariff Ruling
06:31

Middle East Geoeconomics Lead for Bloomberg Economics, Dina Esfandiary, Talks US Military, Middle East Tensions
07:38